# 2025年12月5日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 我们持异议：从2025年社区获得性肺炎指南中汲取的教训

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41340515](https://pubmed.ncbi.nlm.nih.gov/41340515)
**期刊：** Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
**PMID：** 41340515
**DOI：** 10.1093/cid/ciaf626

### 第一部分 原文与翻译

**英文原标题：** We Dissent: Lessons From the 2025 Community-Acquired Pneumonia (CAP) Guidelines.

**英文摘要原文：**
Clinical practice guidelines profoundly influence patient care, making transparency, rigor, and fairness in their development essential. The 2025 community-acquired pneumonia (CAP) guideline update, developed by the American Thoracic Society (ATS) and initially co-sponsored by the Infectious Diseases Society of America (IDSA), included a recommendation to prescribe antibacterials for CAP upon detection of a respiratory viral pathogen. Here, we acknowledge the guidelines' strengths with respect to supporting shorter treatment duration but highlight the lack of supporting data for antibacterial therapy in CAP with a respiratory virus. We additionally reflect on shortcomings in the guideline development process itself, which may have led to this recommendation, including meeting logistics, communication, and methodology, using these observations to offer suggestions for future infectious diseases guidelines panels. Despite the unfortunate outcome, we commend IDSA for their difficult but principled decision to withdraw support, preserving stewardship priorities and the commitment to first do no harm.

**中文摘要译文：**
临床实践指南深刻影响患者诊疗，因此其制定过程的透明度、严谨性和公平性至关重要。由美国胸科学会（ATS）制定、最初由美国感染病学会（IDSA）共同发起的2025年社区获得性肺炎（CAP）指南更新，包含了一项建议：在检测到呼吸道病毒病原体时，为CAP患者开具抗菌药物。在此，我们承认该指南在支持缩短治疗疗程方面的优势，但强调对于伴有呼吸道病毒的CAP患者进行抗菌治疗缺乏支持数据。我们进一步反思了指南制定过程本身的缺陷，这些缺陷可能导致此项建议的产生，包括会议组织、沟通和方法学等方面，并利用这些观察结果为未来的感染病指南制定小组提供建议。尽管结果令人遗憾，我们仍赞扬IDSA做出艰难但有原则的决定，撤回对该指南的支持，以维护抗菌药物管理优先原则和'首先不伤害'的承诺。

### 第二部分 AI 大师评价

本研究采用批判性分析方法，对2025年社区获得性肺炎指南更新中关于病毒性肺炎使用抗菌药物的争议性建议进行了深入剖析。研究核心目的是揭示指南制定过程中的方法学缺陷，并强调循证医学原则在临床实践指南制定中的重要性。关键发现包括：指南推荐缺乏充分证据支持，制定过程存在组织、沟通和方法学等多方面问题。该研究的创新性在于从内部视角对权威指南制定过程进行系统性反思，具有重要的临床价值——警示临床医生应审慎对待指南建议，特别是当推荐缺乏高质量证据支持时。研究局限性在于仅基于单一指南事件进行分析，但其提出的改进建议对提升未来感染病指南的严谨性和可信度具有深远影响。

---

## 2. 美国感染病学会（IDSA）立场声明：为何IDSA未认可2025年社区获得性肺炎指南更新

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41340493](https://pubmed.ncbi.nlm.nih.gov/41340493)
**期刊：** Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
**PMID：** 41340493
**DOI：** 10.1093/cid/ciaf625

### 第一部分 原文与翻译

**英文原标题：** Infectious Diseases Society of America (IDSA) Position Statement: Why IDSA Did Not Endorse the Community-Acquired Pneumonia Guidelines 2025 Update.

**英文摘要原文：**
The American Thoracic Society recently released updated community-acquired肺炎 (CAP) guidelines. The Infectious Diseases Society of America (IDSA) agreed with 8 of the 10 recommendations in the guidelines but declined to endorse the guidelines because they include recommendations for use of antibiotics in outpatients with comorbidities and inpatients with nonsevere CAP who test positive for respiratory viruses. It is noted in the guidelines that bacterial coinfections are common and that delaying antibiotics may be harmful. IDSA notes, however, that nondiscriminatory use of antibiotics for patients with CAP and positive viral assays confers more risks than benefits. Most patients do not have bacterial coinfections, and briefly withholding antibiotics for patients with nonsevere illness to clarify the diagnosis is safe. In this era of precision medicine, IDSA instead recommends individualized, dynamic decision-making that takes into account each patient´s evolving trajectory, severity of illness and balance of clinical features for and against coinfection.

**中文摘要译文：**
美国胸科学会近期发布了更新的社区获得性肺炎（CAP）指南。美国感染病学会（IDSA）同意该指南中的10项建议中的8项，但拒绝认可该指南，因为其中包含了针对合并症的门诊患者以及呼吸道病毒检测阳性的非重症CAP住院患者使用抗生素的建议。指南中指出细菌合并感染很常见，延迟使用抗生素可能有害。然而，IDSA指出，对于CAP患者且病毒检测阳性者，不加区分地使用抗生素带来的风险大于获益。大多数患者没有细菌合并感染，对于非重症患者，短暂暂停使用抗生素以明确诊断是安全的。在精准医学时代，IDSA反而建议采用个体化、动态的决策制定，考虑每位患者不断演变的病程轨迹、疾病严重程度以及支持与反对合并感染的临床特征平衡。

### 第二部分 AI 大师评价

本研究通过美国感染病学会（IDSA）的立场声明，系统阐述了其未认可美国胸科学会2025年社区获得性肺炎指南更新的核心原因。研究采用循证医学和临床实践分析的方法，对比了不同指南在抗生素使用策略上的分歧。关键发现显示，IDSA强调对于病毒检测阳性的CAP患者，应避免不加区分地使用抗生素，而应采取个体化、动态的临床决策。该研究的创新性在于将精准医学理念融入感染病管理，强调基于患者具体情况的个体化治疗而非一刀切方案，对减少抗生素滥用、遏制细菌耐药性具有重要临床价值。然而，研究局限性在于缺乏大规模临床数据支持其建议，且可能增加临床决策的复杂性。

---

## 3. 通气设置对恢复自主呼吸的低氧血症患者摆动呼吸及呼气肌活动的影响

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41339937](https://pubmed.ncbi.nlm.nih.gov/41339937)
**期刊：** Critical care (London, England)
**PMID：** 41339937
**DOI：** 10.1186/s13054-025-05784-y

### 第一部分 原文与翻译

**英文原标题：** Influence of ventilatory settings on pendelluft and expiratory muscle activity in hypoxemic patients resuming spontaneous breathing.

**英文摘要原文：**
BACKGROUND: Pendelluft and expiratory muscle activity during spontaneous breathing should be minimized to reduce potential harmful effects. This study aimed to describe pendelluft and expiratory muscle activity in hypoxemic patients recovering spontaneous breathing after ≥ 72 h of lung-protective, fully controlled mechanical ventilation (MV) and assess the effect of pressure support ventilation (PSV) and positive end-expiratory pressure (PEEP).

METHODS: A physiological, randomized crossover study was conducted in hypoxemic patients receiving three levels of PSV: 5, 10, and 15 cmH₂O, and two PEEP levels: based on electrical impedance tomography before spontaneous breathing (PEEP) or according to PEEP-FiO tables (PEEP). Pendelluft was defined as the percentage of volume displaced from non-dependent to dependent lung regions during inspiration. Expiratory muscle activity was assessed by the expiratory rise in gastric pressure (ΔPga), and inspiratory effort was estimated using muscular pressure (Pmus). Statistical analyses included linear mixed-effects models and mediation analyses.

RESULTS: Fifteen patients were enrolled (mean PaO/FiO ratio: 262 ± 51 mmHg; median duration of MV: 9 [5-13] days; 6 females). PEEP was 11 [10-13] cmH₂O and PEEP 6 [5-7] cmH₂O. Expiratory muscle activity was observed in 13 patients. Compared to PS 5 cmHO, PS to 10 and 15 cmHO, adjusted for PEEP, significantly reduced both pendelluft and ΔPga (p < 0.001). When adjusted for PS, PEEP was associated with a slight reduction in pendelluft (p = 0.039) but a concomitant increase in ΔPga (p = 0.007) compared to PEEP. The mediation analysis revealed a significant negative mediating effect of ΔPga on the relationship between PEEP and pendelluft (p < 0.001). Pmus, which was also significantly associated with pendelluft magnitude (p < 0.001), mediated the effect of PS on reducing pendelluft (p = 0.048), but not that of PEEP (p = 0.46).

CONCLUSIONS: In patients with ARDS transitioning to spontaneous breathing, increasing PS reduces pendelluft and expiratory muscle activity. Higher PEEP can decrease pendelluft, but its effect can be counteracted by increased expiratory activity.

**中文摘要译文：**
背景：在自主呼吸期间，应尽量减少摆动呼吸和呼气肌活动，以降低潜在的有害影响。本研究旨在描述接受≥72小时肺保护性、完全控制性机械通气（MV）后恢复自主呼吸的低氧血症患者的摆动呼吸和呼气肌活动，并评估压力支持通气（PSV）和呼气末正压（PEEP）的影响。

方法：在一组低氧血症患者中进行了一项生理学、随机交叉研究，患者接受三种水平的PSV：5、10和15 cmH₂O，以及两种PEEP水平：基于自主呼吸前电阻抗断层扫描的PEEP（PEEP）或根据PEEP-FiO₂表的PEEP（PEEP）。摆动呼吸定义为吸气期间从非依赖区向依赖区肺区域位移的体积百分比。通过胃压的呼气上升（ΔPga）评估呼气肌活动，并使用肌肉压（Pmus）估计吸气努力。统计分析包括线性混合效应模型和中介分析。

结果：共纳入15名患者（平均PaO₂/FiO₂比值：262±51 mmHg；MV中位持续时间：9[5-13]天；6名女性）。PEEP为11[10-13] cmH₂O，PEEP为6[5-7] cmH₂O。在13名患者中观察到呼气肌活动。与PS 5 cmH₂O相比，调整PEEP后，PS增加到10和15 cmH₂O显著减少了摆动呼吸和ΔPga（p<0.001）。调整PS后，与PEEP相比，PEEP与摆动呼吸的轻微减少相关（p=0.039），但同时伴随ΔPga的增加（p=0.007）。中介分析显示ΔPga对PEEP与摆动呼吸之间的关系具有显著的负向中介效应（p<0.001）。与摆动呼吸幅度也显著相关的Pmus（p<0.001）介导了PS减少摆动呼吸的效应（p=0.048），但未介导PEEP的效应（p=0.46）。

结论：在ARDS患者过渡到自主呼吸过程中，增加PS可减少摆动呼吸和呼气肌活动。较高的PEEP可以减少摆动呼吸，但其效果可能被增加的呼气活动所抵消。

### 第二部分 AI 大师评价

本研究旨在探讨通气设置对ARDS患者恢复自主呼吸时摆动呼吸和呼气肌活动的影响。研究采用随机交叉设计，系统评估了不同PSV和PEEP水平对这两个关键生理指标的作用。核心发现表明，增加压力支持能有效减少摆动呼吸和呼气肌活动，而PEEP虽能轻微减少摆动呼吸，但会伴随呼气肌活动的增加。该研究的创新性在于首次系统量化了通气设置对摆动呼吸和呼气肌活动的交互影响，为ARDS患者脱机策略提供了重要生理学依据。临床价值显著，有助于优化脱机过程中的通气参数设置，但样本量较小是其局限性，需要在更大规模研究中验证。

---

## 4. 单细胞多组学图谱揭示成人与儿童脓毒症中解剖部位特异的免疫特征

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41339491](https://pubmed.ncbi.nlm.nih.gov/41339491)
**期刊：** Nature immunology
**PMID：** 41339491
**DOI：** 10.1038/s41590-025-02345-x

### 第一部分 原文与翻译

**英文原标题：** Single-cell multi-omic landscape reveals anatomical-specific immune features in adult and pediatric sepsis.

**英文摘要原文：**
The anatomical source of infection is a major determinant of sepsis outcomes; however, how distinct sites shape immunity remains unclear. Here we applied multi-omic profiling, integrating single-cell transcriptomics, single-cell T cell receptor and B cell receptor sequencing, CITE-seq, bulk RNA sequencing and plasma proteomics, to analyze peripheral blood mononuclear cells and plasma from 281 adult and pediatric individuals with sepsis and controls. We identified an NR4A2 central memory CD4 T cell subset enriched in abdominal, pulmonary and skin sepsis, with features of exhaustion; genetic perturbations showed Nr4a2 loss improved survival, while overexpression worsened it. Proinflammatory CD8 T, natural killer and natural killer T subsets expressing CCL4, CCL3 and tumor necrosis factor expanded in adult abdominal and pulmonary sepsis, while pediatric pulmonary sepsis featured proliferative CD14 monocytes, findings validated in external single-cell cohorts and confirmed in 164 independent individuals. Plasma proteomics revealed shared mediators including interleukin-6 and EN-RAGE across anatomical sites and ages. Together, our findings delineate anatomical-specific and age-specific immune programs in sepsis, highlighting candidate targets for precision immunotherapy.

**中文摘要译文：**
感染解剖部位是脓毒症预后的主要决定因素；然而，不同部位如何塑造免疫应答仍不清楚。本研究应用多组学分析，整合单细胞转录组学、单细胞T细胞受体和B细胞受体测序、CITE-seq、批量RNA测序和血浆蛋白质组学，分析了来自281名成人和儿童脓毒症患者及对照的外周血单个核细胞和血浆。我们鉴定出一个NR4A2中央记忆CD4 T细胞亚群，在腹部、肺部和皮肤脓毒症中富集，具有耗竭特征；遗传扰动显示Nr4a2缺失可提高生存率，而过表达则使其恶化。表达CCL4、CCL3和肿瘤坏死因子的促炎性CD8 T细胞、自然杀伤细胞和自然杀伤T细胞亚群在成人腹部和肺部脓毒症中扩增，而儿童肺部脓毒症则以增殖性CD14单核细胞为特征，这些发现在外部单细胞队列中得到验证，并在164名独立个体中得到确认。血浆蛋白质组学揭示了跨解剖部位和年龄的共享介质，包括白细胞介素-6和EN-RAGE。总之，我们的研究结果描绘了脓毒症中解剖部位特异性和年龄特异性的免疫程序，突出了精准免疫治疗的候选靶点。

### 第二部分 AI 大师评价

本研究通过整合多种单细胞和批量组学技术，系统解析了不同解剖部位感染导致的脓毒症中免疫应答的异质性。研究创新性地发现NR4A2中央记忆CD4 T细胞在特定部位脓毒症中的富集及其与预后的关联，并揭示了成人与儿童脓毒症免疫特征的显著差异。该研究为脓毒症的精准免疫治疗提供了重要的分子靶点，但基于外周血样本的分析可能无法完全反映局部组织的免疫微环境变化，未来需要结合组织样本进行更全面的验证。

---

## 5. 未经治疗的多发性硬化症患者脑脊液纵向蛋白质组学分析揭示疾病生物学演变

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41339376](https://pubmed.ncbi.nlm.nih.gov/41339376)
**期刊：** Nature communications
**PMID：** 41339376
**DOI：** 10.1038/s41467-025-65154-8

### 第一部分 原文与翻译

**英文原标题：** Longitudinal proteomic profiling of cerebrospinal fluid in untreated multiple sclerosis defines evolving disease biology.

**英文摘要原文：**
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system, but the molecular mechanisms underlying its course remain incompletely understood. We measured 4789 cerebrospinal fluid proteins in 1040 samples from 438 individuals with MS and controls followed longitudinally. To isolate disease-related biology, we adjusted for normal aging, sex, while also measuring residual effects of demographic and genetic covariates. Here we show that 3714 proteins are significantly associated with twelve clinical and imaging outcomes, highlighting processes linked to viral infection, disruption of epithelial barriers, stromal cell-mediated tissue remodeling, demyelination, and synaptic and neuronal loss. We also find strong sex-related differences: men show greater activation of pathways associated with tissue injury and disability accumulation, whereas women upregulate neurodevelopmental programs that may promote resilience or repair. These molecular maps of MS natural history provide a framework for understanding disease mechanisms and a resource for future drug development.

**中文摘要译文：**
多发性硬化症（MS）是一种中枢神经系统的慢性炎症性疾病，但其病程的分子机制仍不完全清楚。我们在438名MS患者和对照者的1040个样本中测量了4789种脑脊液蛋白质，进行了纵向随访。为了分离疾病相关的生物学过程，我们调整了正常衰老、性别的影响，同时测量了人口统计学和遗传协变量的残余效应。在此，我们展示了3714种蛋白质与12项临床和影像学结果显著相关，突出了与病毒感染、上皮屏障破坏、基质细胞介导的组织重塑、脱髓鞘以及突触和神经元丢失相关的过程。我们还发现了强烈的性别相关差异：男性显示出与组织损伤和残疾累积相关的通路激活更强，而女性则上调了可能促进恢复或修复的神经发育程序。这些MS自然史的分子图谱为理解疾病机制提供了一个框架，并为未来的药物开发提供了资源。

### 第二部分 AI 大师评价

本研究通过大规模纵向蛋白质组学分析，系统揭示了多发性硬化症疾病进展的分子动态变化。研究团队对438名个体（包括患者和对照）的1040份脑脊液样本进行了4789种蛋白质的检测，并校正了年龄、性别等混杂因素，创新性地构建了MS自然史的分子图谱。关键发现包括：3714种蛋白质与临床/影像学指标显著相关，揭示了病毒感染、上皮屏障破坏、组织重塑等多条病理通路，并首次系统报道了MS病理机制的性别差异——男性偏向组织损伤通路，女性则激活神经修复程序。这项研究为理解MS的异质性进展提供了重要的分子框架，对个体化治疗策略开发和生物标志物发现具有重要价值，但基于脑脊液样本的研究可能限制了其在临床常规应用中的便利性。

---

## 6. 血小板介导的血管周围肥大细胞活化触发小鼠败血症向感染性休克进展

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41339353](https://pubmed.ncbi.nlm.nih.gov/41339353)
**期刊：** Nature communications
**PMID：** 41339353
**DOI：** 10.1038/s41467-025-66978-0

### 第一部分 原文与翻译

**英文原标题：** Platelet-mediated activation of perivascular mast cells triggers progression of sepsis to septic shock in mice.

**英文摘要原文：**
The critical events that trigger sepsis progression into life-threatening septic shock remain unclear. In agreement with reports that link a drop in platelet count to a complicated clinical course in sepsis patients, here we report that, during sepsis, mouse platelets become activated, deposit systemically on vascular walls, and stimulate perivascular mast cells (MC) by releasing platelet activating factor (PAF). In mouse models and patient samples, MC activation correlates with the development of shock in sepsis and is mechanistically linked to shock by inducing systemic hypotension, vascular leakage and microvascular perfusion abnormalities. Preventing platelet or MC activation, or inhibiting the activity of the major MC granule constituent chymase, averts progression from sepsis to shock and reduces mortality of septic mice. Thus, our work establishes that, during sepsis progression, platelet microvascular adhesion leads to MC-mediated vascular changes to culminate in septic shock and septic shock-associated mortality.

**中文摘要译文：**
触发败血症进展为危及生命的感染性休克的关键事件仍不清楚。与报道中血小板计数下降与败血症患者复杂临床病程相关的观点一致，本文报道在败血症期间，小鼠血小板被激活，系统性沉积在血管壁上，并通过释放血小板活化因子（PAF）刺激血管周围肥大细胞（MC）。在小鼠模型和患者样本中，MC活化与败血症中休克的发生相关，并通过诱导系统性低血压、血管渗漏和微血管灌注异常与休克存在机制性关联。预防血小板或MC活化，或抑制主要MC颗粒成分糜蛋白酶活性，可避免败血症向休克进展，并降低败血症小鼠的死亡率。因此，我们的研究证实，在败血症进展过程中，血小板微血管黏附导致MC介导的血管变化，最终引发感染性休克及感染性休克相关死亡。

### 第二部分 AI 大师评价

本研究旨在阐明败血症进展为感染性休克的关键机制。通过结合小鼠模型和患者样本分析，研究者发现血小板活化后沉积于血管壁，通过释放PAF激活血管周围肥大细胞，进而引发系统性低血压、血管渗漏等病理变化。该研究的创新性在于首次揭示了血小板-肥大细胞轴在败血症向休克转化中的核心作用，为临床干预提供了新的靶点（如抑制糜蛋白酶活性）。研究具有重要的临床转化价值，但需注意其基于小鼠模型的发现需在人类中进一步验证，且具体信号通路细节有待深入探索。

---

## 7. USP16 S-亚硝基化通过抑制KDM1A介导的谷胱甘肽稳态加重冠状动脉微栓塞诱导的心肌损伤

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41339351](https://pubmed.ncbi.nlm.nih.gov/41339351)
**期刊：** Nature communications
**PMID：** 41339351
**DOI：** 10.1038/s41467-025-66943-x

### 第一部分 原文与翻译

**英文原标题：** USP16 S-nitrosylation aggravates coronary microembolization-induced myocardial injury via repressing KDM1A-mediated glutathione homeostasis.

**英文摘要原文：**
Coronary microembolization (CME) is a serious cardiovascular complication that causes severe cardiac dysfunction and arrhythmias. Glutathione (GSH) exhaustion-induced oxidative stress is a key contributor to CME. Here, we explore the molecular mechanisms underlying GSH imbalance during CME. We show that CME induces myocardial injury by disturbing GSH homeostasis, which is ameliorated by glutamate-cysteine ligase modifier subunit (GCLM) or glutaminase (GLS) overexpression. Lysine-specific histone demethylase 1A (KDM1A) removes H3K9me1/2 from the promoter regions of GCLM and GLS to promote their epigenetic expression, thereby maintaining GSH homeostasis in CME. KDM1A is ubiquitinated at the K355 site during CME via inhibiting ubiquitin-specific peptidase 16 (USP16)-mediated deubiquitination. Inducible nitric oxide synthase (iNOS) facilitates S-nitrosylation (SNO) of USP16 at the C731 site, contributing to KDM1A ubiquitination and causing GSH imbalance during CME. Altogether, SNO-USP16 inhibition stabilizes the KDM1A protein to epigenetically activate GCLM and GLS, thus maintaining GSH homeostasis and relieving CME-induced myocardial injury.

**中文摘要译文：**
冠状动脉微栓塞（CME）是一种严重的心血管并发症，可导致严重的心功能障碍和心律失常。谷胱甘肽（GSH）耗竭诱导的氧化应激是CME的关键因素。在此，我们探讨了CME期间GSH失衡的分子机制。我们发现CME通过扰乱GSH稳态诱导心肌损伤，而过表达谷氨酸-半胱氨酸连接酶修饰亚基（GCLM）或谷氨酰胺酶（GLS）可改善这一损伤。赖氨酸特异性组蛋白去甲基化酶1A（KDM1A）从GCLM和GLS的启动子区域去除H3K9me1/2，以促进其表观遗传表达，从而在CME中维持GSH稳态。在CME期间，KDM1A在K355位点通过抑制泛素特异性肽酶16（USP16）介导的去泛素化而被泛素化。诱导型一氧化氮合酶（iNOS）促进USP16在C731位点的S-亚硝基化（SNO），导致KDM1A泛素化，并在CME期间引起GSH失衡。总之，抑制SNO-USP16可稳定KDM1A蛋白，从而表观遗传激活GCLM和GLS，维持GSH稳态并减轻CME诱导的心肌损伤。

### 第二部分 AI 大师评价

本研究旨在阐明冠状动脉微栓塞（CME）诱导心肌损伤的表观遗传调控机制，聚焦于谷胱甘肽稳态失衡的关键环节。研究采用分子生物学方法，揭示了USP16 S-亚硝基化通过促进KDM1A泛素化降解，进而抑制GCLM和GLS表达，最终导致GSH耗竭的级联反应。创新性地发现了iNOS-USP16-KDM1A-GCLM/GLS信号轴在CME病理过程中的核心作用，为靶向干预提供了新思路。该研究具有重要的临床转化价值，不仅深化了对CME发病机制的理解，更为开发以USP16 S-亚硝基化为靶点的治疗策略奠定了理论基础，但需进一步验证该通路在人体中的功能及药物干预的可行性。

---

## 8. APIP通过结合TRAF6调控经典NLRP3和非经典Caspase-11/4炎症小体的启动

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41339302](https://pubmed.ncbi.nlm.nih.gov/41339302)
**期刊：** Nature communications
**PMID：** 41339302
**DOI：** 10.1038/s41467-025-65893-8

### 第一部分 原文与翻译

**英文原标题：** APIP regulates the priming of canonical NLRP3 and non-canonical Caspase-11/4 inflammasomes by binding to TRAF6.

**英文摘要原文：**
Apaf-1-interacting protein (APIP) has been implicated in inflammation-related processes, including myocardial infarction and cancer progression. However, its role in systemic inflammation remains elusive. Here, we investigate the APIP-mediated regulation of inflammasome activity in mice and human macrophages. Loss of APIP in the myeloid lineage (Apip cKO mice) compromises the activation of canonical NLRP3 and non-canonical caspase-11 inflammasomes, reducing pyroptosis in bone marrow-derived macrophages (BMDM). Conversely, these inflammatory responses are enhanced in BMDMs from APIP-transgenic mice. Consistently, APIP knockdown in human macrophages inhibits the activation of NLRP3 and caspase-4 inflammasomes. Mechanistically, APIP binds to TRAF6, activating downstream NF-κB and JNK signaling and facilitating the priming of both inflammasomes. Importantly, systemic inflammation induced by LPS or bacterial infection is attenuated in Apip cKO mice but exacerbated in APIP-transgenic mice. Thus, our findings suggest that APIP is crucial in regulating both canonical and non-canonical inflammasomes, presenting a potential therapeutic target for inflammatory diseases.

**中文摘要译文：**
Apaf-1相互作用蛋白（APIP）已被证实参与炎症相关过程，包括心肌梗死和癌症进展。然而，其在全身性炎症中的作用尚不明确。在此，我们研究了APIP介导的小鼠和人类巨噬细胞中炎症小体活性的调控。髓系谱系中APIP的缺失（Apip cKO小鼠）会损害经典NLRP3和非经典caspase-11炎症小体的激活，减少骨髓来源巨噬细胞（BMDM）的细胞焦亡。相反，来自APIP转基因小鼠的BMDM中这些炎症反应增强。一致地，人类巨噬细胞中APIP的敲低抑制了NLRP3和caspase-4炎症小体的激活。机制上，APIP结合TRAF6，激活下游NF-κB和JNK信号通路，促进两种炎症小体的启动。重要的是，LPS或细菌感染诱导的全身性炎症在Apip cKO小鼠中减弱，但在APIP转基因小鼠中加剧。因此，我们的研究结果表明APIP在调控经典和非经典炎症小体中至关重要，为炎症性疾病提供了一个潜在的治疗靶点。

### 第二部分 AI 大师评价

本研究旨在阐明APIP蛋白在全身性炎症中的调控机制，通过构建髓系特异性敲除和转基因小鼠模型，结合人类巨噬细胞实验，系统探究了APIP对经典NLRP3和非经典caspase-11/4炎症小体的调控作用。研究发现APIP通过结合TRAF6激活NF-κB和JNK信号通路，从而促进炎症小体的启动，这一机制在LPS或细菌感染诱导的全身性炎症模型中得到了验证。该研究的创新性在于首次揭示了APIP作为炎症小体启动的关键调控因子，其发现不仅深化了对炎症反应分子机制的理解，更为炎症性疾病的靶向治疗提供了新的潜在靶点，具有重要的临床转化价值。然而，研究主要聚焦于巨噬细胞系统，未来需要进一步探索APIP在其他免疫细胞类型中的作用及其在特定疾病模型中的治疗潜力。

---

## 9. 佩格西他普兰在C3肾小球病和免疫复合物性膜增生性肾小球肾炎中的试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41337715](https://pubmed.ncbi.nlm.nih.gov/41337715)
**期刊：** The New England journal of medicine
**PMID：** 41337715
**DOI：** 10.1056/NEJMoa2501510

### 第一部分 原文与翻译

**英文原标题：** Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN.

**英文摘要原文：**
BACKGROUND: C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis (MPGN) generally result in glomerular C3 deposition and irreversible kidney damage. The efficacy and safety of pegcetacoplan, a C3 and C3b inhibitor, in persons with C3 glomerulopathy or primary immune-complex MPGN are unclear. METHODS: We conducted a phase 3, double-blind, placebo-controlled trial involving adolescents and adults with C3 glomerulopathy or primary immune-complex MPGN, including those with native kidney disease and those with disease recurrence after transplantation. Patients were randomly assigned in a 1:1 ratio to receive pegcetacoplan or placebo. The primary end point was the log-transformed ratio of the urinary protein-to-creatinine ratio at week 26 as compared with baseline. RESULTS: A total of 124 patients underwent randomization. The change in proteinuria (as measured by the log-transformed ratio to baseline in the urinary protein-to-creatinine ratio) was significantly greater with pegcetacoplan than with placebo (geometric mean of the urinary protein-to-creatinine ratio, -67.2% [95% confidence interval {CI}, -74.9 to -57.2] vs. 2.9% [95% CI, -8.6 to 15.9]). The difference represents a relative reduction of 68.1% (95% CI, 57.3 to 76.2) as compared with placebo. In hierarchical testing of five secondary end points, significantly higher percentages of patients in the pegcetacoplan group than in the placebo group met the composite renal end-point criteria (stabilization of estimated glomerular filtration rate [eGFR] and ≥50% reduction in urinary protein-to-creatinine ratio) (49% vs. 3%) and had at least a 50% reduction in the protein-to-creatinine ratio (60% vs. 5%). Among 69 patients with evaluable kidney-biopsy samples, the change in the activity score of the C3 glomerulopathy histologic index did not differ significantly between the two groups; subsequent end points (decrease in C3 staining and change in eGFR) were not formally tested. Pegcetacoplan was not associated with more adverse events than placebo. No serious infections from encapsulated bacteria occurred; 1 patient receiving pegcetacoplan died from coronavirus disease 2019 pneumonia. No allograft rejection or loss occurred. CONCLUSIONS: Pegcetacoplan resulted in a significantly greater reduction in proteinuria than placebo among patients with C3 glomerulopathy or primary immune-complex MPGN. (Funded by Apellis Pharmaceuticals and Sobi [Swedish Orphan Biovitrum]; VALIANT ClinicalTrials.gov number, NCT05067127.).

**中文摘要译文：**
背景：C3肾小球病和原发性免疫复合物性膜增生性肾小球肾炎（MPGN）通常导致肾小球C3沉积和不可逆的肾脏损伤。佩格西他普兰（一种C3和C3b抑制剂）在C3肾小球病或原发性免疫复合物性MPGN患者中的疗效和安全性尚不明确。方法：我们进行了一项3期、双盲、安慰剂对照试验，纳入了患有C3肾小球病或原发性免疫复合物性MPGN的青少年和成人患者，包括患有原生肾脏疾病的患者以及移植后疾病复发的患者。患者按1:1的比例随机分配接受佩格西他普兰或安慰剂治疗。主要终点是第26周时尿蛋白-肌酐比值与基线相比的对数转换比值。结果：共有124名患者接受了随机分组。佩格西他普兰组的蛋白尿变化（通过尿蛋白-肌酐比值与基线的对数转换比值测量）显著大于安慰剂组（尿蛋白-肌酐比值的几何平均数，-67.2% [95%置信区间{CI}，-74.9至-57.2] vs. 2.9% [95% CI，-8.6至15.9]）。这一差异代表与安慰剂相比相对减少了68.1%（95% CI，57.3至76.2）。在对五个次要终点的分层检验中，佩格西他普兰组中符合复合肾脏终点标准（估计肾小球滤过率[eGFR]稳定且尿蛋白-肌酐比值降低≥50%）的患者比例显著高于安慰剂组（49% vs. 3%），且尿蛋白-肌酐比值降低至少50%的患者比例也更高（60% vs. 5%）。在69名具有可评估肾脏活检样本的患者中，两组间C3肾小球病组织学指数活动评分的变化无显著差异；后续终点（C3染色减少和eGFR变化）未进行正式检验。佩格西他普兰组的不良事件发生率不高于安慰剂组。未发生来自荚膜细菌的严重感染；1名接受佩格西他普兰治疗的患者死于2019冠状病毒病肺炎。未发生移植物排斥或丢失。结论：在C3肾小球病或原发性免疫复合物性MPGN患者中，佩格西他普兰比安慰剂能显著更大程度地减少蛋白尿。（由Apellis Pharmaceuticals和Sobi[瑞典孤儿生物维特鲁姆]资助；VALIANT临床试验注册号，NCT05067127。）

### 第二部分 AI 大师评价

本研究旨在评估C3抑制剂佩格西他普兰在C3肾小球病和免疫复合物性MPGN中的疗效与安全性。通过一项3期随机对照试验，研究证实该药物能显著降低蛋白尿达68.1%，且49%的患者达到复合肾脏终点，展现了明确的治疗获益。该研究的创新性在于首次针对这一罕见肾脏疾病的补体靶向治疗提供了高级别循证证据，具有重要的临床转化价值。然而，研究在组织病理学改善方面未显示显著差异，且样本量有限，提示未来需要更长期的随访以评估对肾功能硬终点的持久影响。

---

## 10. 肺泡2型上皮细胞蛋白质稳态失调促进纤维化巨噬细胞迁移抑制因子-CD74信号传导。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41337540](https://pubmed.ncbi.nlm.nih.gov/41337540)
**期刊：** Science translational medicine
**PMID：** 41337540
**DOI：** 10.1126/scitranslmed.adr2277

### 第一部分 原文与翻译

**英文原标题：** Dysregulated alveolar type 2 epithelial cell proteostasis promotes fibrogenic macrophage migration inhibitory factor-CD74 signaling.

**英文摘要原文：**
Aberrant proteostasis in alveolar type 2 epithelial cells (AEC2s) contributes to idiopathic pulmonary fibrosis (IPF), but the role of the ubiquitin-proteasome system (UPS) is unclear. Here, we show that UPS disruption in AEC2s amplifies profibrotic signaling to macrophages through macrophage migration inhibitory factor (MIF) family proteins in several models. Modeling UPS disruption with an AEC2-specific cullin 3 () deletion produced spontaneous fibrosis in a physiological aging mouse model and exacerbated fibrosis in the bleomycin-induced lung injury model. This was accompanied by expansion of transitional epithelial states and increased MIF and MIF-2 in lung tissue and bronchoalveolar lavage fluid (BALF) in the model. Global or conditional AEC2-specific deletions of  or  attenuated fibrosis in the bleomycin-treated mouse model, as did conditional deletions of , the cognate receptor for MIF and MIF-2, in C-X3-C motif chemokine receptor 1 ()-expressing and platelet factor 4 ()-expressing cells. Pharmacological inhibition of MIF attenuated fibrosis in bleomycin-treated and transforming growth factor-β1 () transgenic mouse models and in ex vivo human precision-cut lung slices treated with fibrotic cocktail. In study participants with IPF, BALF MIF was elevated compared with that in study participants without IPF. In participants with IPF, BALF MIF greater than 4000 picograms per milliliter was associated with increased mortality compared with participants with IPF with lower MIF. Together, these findings define a UPS-sensitive epithelial-macrophage signaling connection and identify MIF-CD74 cross-talk as a potential therapeutic target in fibrotic lung disease.

**中文摘要译文：**
肺泡2型上皮细胞（AEC2s）中异常的蛋白质稳态导致特发性肺纤维化（IPF），但泛素-蛋白酶体系统（UPS）的作用尚不清楚。在此，我们发现在多种模型中，AEC2s中的UPS破坏通过巨噬细胞迁移抑制因子（MIF）家族蛋白放大了向巨噬细胞的促纤维化信号传导。使用AEC2特异性cullin 3缺失模拟UPS破坏，在生理衰老小鼠模型中产生了自发性纤维化，并加剧了博来霉素诱导的肺损伤模型中的纤维化。这伴随着过渡性上皮状态的扩展以及模型中肺组织和支气管肺泡灌洗液（BALF）中MIF和MIF-2的增加。在博来霉素处理的小鼠模型中，全局或条件性AEC2特异性MIF或MIF-2缺失减轻了纤维化，在表达C-X3-C基序趋化因子受体1和表达血小板因子4的细胞中，MIF和MIF-2的已知受体CD74的条件性缺失也减轻了纤维化。MIF的药理学抑制减轻了博来霉素处理和转化生长因子-β1转基因小鼠模型以及用纤维化混合物处理的离体人精确切割肺切片中的纤维化。在IPF研究参与者中，与无IPF的参与者相比，BALF MIF升高。在IPF参与者中，BALF MIF大于4000皮克/毫升与死亡率增加相关，而MIF较低的IPF参与者则不然。总之，这些发现定义了UPS敏感的上皮-巨噬细胞信号传导连接，并确定MIF-CD74相互作用作为纤维化肺病中潜在的治疗靶点。

### 第二部分 AI 大师评价

本研究旨在阐明肺泡2型上皮细胞蛋白质稳态失调在特发性肺纤维化中的分子机制，特别聚焦于泛素-蛋白酶体系统破坏如何通过巨噬细胞迁移抑制因子信号通路驱动纤维化进程。研究采用多模型验证策略，包括基因工程小鼠模型、药理学干预和临床样本分析，系统揭示了UPS-MIF-CD74轴在肺纤维化中的核心作用。创新性地发现了上皮细胞蛋白质稳态失调与巨噬细胞激活之间的信号连接，并证实了BALF中MIF水平与IPF患者预后的相关性，为开发靶向MIF-CD74通路的抗纤维化疗法提供了重要理论依据。虽然研究在机制探索方面较为深入，但临床转化仍需更大规模的验证研究。

---

速递结束，祝您工作愉快！